Pharm Res 2007, 24: 1720–1728.CrossRefPubMed 15. Mistry P, Stewart AJ, Dangerfield W, Okiji S, Liddle C, Bootle D, Plumb JA, Templeton D, Charlton P: In vitro and in vivo reversal of P-glycoprotein-mediated

multidrug resistance by a novel potent modulator, this website XR9576. Cancer Res 2001, 61: 749–758.PubMed 16. Fox E, Bates SE: Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor. Expert Rev Anticancer Ther 2007, 7: 447–459.CrossRefPubMed 17. Lepper ER, Hicks JK, Verweij J, Zhai S, Figg WD, Sparreboom A: Determination of midazolam in human plasma by liquid chromatography with mass-spectrometric detection. J Chromatogr B Analyt Technol Biomed Life Sci 2004, 806: 305–310.CrossRefPubMed 18. Beppu K, Jaboine J, Merchant MS, Mackall CL, Thiele CJ: Effect of imatinib mesylate selleck on neuroblastoma tumorigenesis and vascular endothelial growth factor expression. J Natl Cancer Inst 2004, 96: 46–55.CrossRefPubMed 19. Bihorel S, Camenisch G, Lemaire M, Scherrmann JM: Modulation of the Brain Distribution of Imatinib and its Metabolites in Mice by Valspodar, Zosuquidar and Elacridar. Pharm Res 2007, 24 (9) : 1720–8.CrossRefPubMed 20. Choo EF, Kurnik D, Muszkat M, Ohkubo T, Shay SD, Higginbotham JN, Glaeser H, Kim RB, Wood AJ, Wilkinson GR: Differential in vivo sensitivity to inhibition of P-glycoprotein located in lymphocytes, testes,

and the blood-brain barrier. J Pharmacol Exp Ther 2006, 317: 1012–1018.CrossRefPubMed 21. Dantzig AH, de Alwis DP, Burgess M: Considerations in the design and development of transport inhibitors

as adjuncts to drug therapy. Adv Drug Deliv Rev 2003, 55: 133–150.CrossRefPubMed Competing interests The authors declare that they have no competing interests. Authors’ contributions ERG participated in study design, BCKDHB performed analytical and animal experiments, carried out all statistical analyses and drafted the manuscript. NFS participated in study design and performed animal experiments. WDF participated in study design and helped to draft the manuscript. AS participated in study design, performed animal experiments and helped to draft the manuscript. All authors approved the final manuscript.”
“Background GSK2245840 clinical trial cervical cancer is the most common malignant gynecological cancer, and lymphatic metastasis is one of the most important metastatic routes of this cancer. The involvement of the lymphatic node is usually one of the factors predicting the prognosis. Along with the development of specific markers of lymphatic endothelium [1] and the improvement of isolation techniques for lymphatic endothelial cells [2], the role of tumor lymphangiogenesis in the metastasis of early-stage cervical carcinoma is gradually becoming a research focus. Even so, the mechanism of the tumor lymphatic metastasis is still largely unknown and there is a great deal of debate over various aspects of research in the field.